Quantum Biopharma (QNTM) Income from Non-Controlling Interests (2020 - 2026)

Quantum Biopharma (QNTM) has 7 years of Income from Non-Controlling Interests data on file, last reported at $13.8 million in Q1 2026.

• For the quarter ending Q1 2026, Income from Non-Controlling Interests rose 57.37% year-over-year to $13.8 million; the trailing twelve-month figure through Mar 2026 stood at -$41.5 million (down 1150.97% YoY), and the FY2025 full-year result was -$27.0 million, down 80.73% from the prior year.
• Income from Non-Controlling Interests climbed to $13.8 million in Q1 2026, from -$50.2 million in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $13.8 million in Q1 2026 to a low of -$50.2 million in Q4 2025.
• A 5-year average of -$4.8 million and a median of -$2.1 million in 2024 frame the typical range for Income from Non-Controlling Interests.
• Across the five-year window, Income from Non-Controlling Interests soared 5726.7% in 2024 and plunged 820.24% in 2025, its largest moves.
• Tracing QNTM's Income from Non-Controlling Interests over 5 years: stood at $5.9 million in 2022, then tumbled by 407.51% to -$18.2 million in 2023, then surged by 69.95% to -$5.5 million in 2024, then sank by 820.24% to -$50.2 million in 2025, then jumped by 127.39% to $13.8 million in 2026.
• Business Quant data shows QNTM's Income from Non-Controlling Interests at $13.8 million in Q1 2026, -$50.2 million in Q4 2025, and $4.7 million in Q3 2025.